Role of FDG PET/CT in Staging of Recurrent Ovarian Cancer

被引：57

作者：

Son, Hongju ^{[1
]}

Khan, Shahid M. ^{[1
]}

Rahaman, Jamal ^{[2
]}

Cameron, Katherine L. ^{[1
]}

Prasad-Hayes, Monica ^{[2
]}

Chuang, Linus ^{[2
]}

Machac, Josef ^{[1
]}

Heiba, Sherif ^{[1
]}

Kostakoglu, Lale ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Dept Radiol, Div Nucl Med, New York, NY 10029 USA

[2] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Med, Div Gynecol Oncol, New York, NY 10029 USA

来源：

RADIOGRAPHICS | 2011年 / 31卷 / 02期

关键词：

POSITRON-EMISSION-TOMOGRAPHY; LYMPH-NODE INVOLVEMENT; SERUM CA-125 LEVELS; NEOADJUVANT CHEMOTHERAPY; DEBULKING SURGERY; FOLLOW-UP; CT; CARCINOMA; IMPACT; METASTASES;

D O I：

10.1148/rg.312105713

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Ovarian cancer is the fifth leading cause of cancer death among women in the United States and has a high likelihood of recurrence despite aggressive treatment strategies. Detection and exact localization of recurrent lesions are critical for guiding management and determining the proper therapeutic approach, which may prolong survival. Because of its high sensitivity and specificity compared with those of conventional techniques such as computed tomography (CT) and magnetic resonance (MR) imaging, fluorine 18 fluorodeoxyglucose positron emission tomography (PET) combined with CT is useful for detection of recurrent or residual ovarian cancer and for monitoring response to therapy. However, PET/CT may yield false-negative results in patients with small, necrotic, mucinous, cystic, or low-grade tumors. In addition, in the posttherapy setting, inflammatory and infectious processes may lead to false-positive PET/CT results. Despite these drawbacks, PET/CT is superior to CT and MR imaging for depiction of recurrent disease. (C) RSNA, 2011.radiographics.rsna.org

引用

页码：569 / U315

页数：16

共 50 条

[1] Staging recurrent ovarian cancer with 18FDG PET/CT
Dragosavac, Sanja
Derchain, Sophie
Caserta, Nelson M. G.
De Souza, Gustavo
[J]. ONCOLOGY LETTERS, 2013, 5 (02) : 593 - 597
[2] A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy
Fagotti, A.
Fanfani, F.
Rossitto, C.
Lorusso, D.
De Gaetano, A. M.
Giordano, A.
Vizzielli, G.
Scambia, G.
[J]. ONCOLOGY, 2008, 75 (3-4) : 152 - 158
[3] The role of FDG PET/CT imaging in detection of recurrent ovarian cancer (OC)
Khan, Shahid
Jiang, Manli
Rahaman, Jamal
Hayes, Monica
Machac, Josef
Heiba, Sherif
Kostakoglu, Lale
[J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51
[4] ROLE OF PET/CT IN RECURRENT OVARIAN CANCER
Batra, K.
Sekhon, R.
Rawal, S.
Giri, S.
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1289 - 1289
[5] Role of Integrated 18-F FDG PET/CT in Recurrent Ovarian Cancer
Sironi, Sandro
Messa, Cristina
Fazio, Ferruccio
[J]. CURRENT MEDICAL IMAGING, 2005, 1 (01) : 1 - 4
[6] The role of FDG PET/CT in preoperative staging of bladder cancer
Aliyev, A.
Yilmaz, S.
Ozhan, M.
Halac, M.
Kanmaz, B.
Sonmezoglu, K.
Demirdag, C.
Obek, C.
Uslu, I.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S426 - S426
[7] Role of FDG-PET/CT in the staging of colorectal cancer
Storto, G.
Mainenti, P.
Varrone, A.
Mainolfi, C.
Salvatore, B.
Caprio, M.
Cella, L.
Soricelli, A.
Pace, L.
Salvatore, M.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S261 - S261
[8] The role of FDG PET/CT in staging gastric cancer: comparison with laparoscopic staging
Zerizer, I.
Parsai, A.
Manca, E.
Du, Y.
Sharma, B.
Mohammadi, B.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S130 - S130
[9] Role of FDG PET/CT in the initial staging of primary colorectal cancer
Agrawal, K.
Sharma, A.
Bhattacharya, A.
Gupta, R.
Mittal, B. R.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S473 - S473
[10] FDG PET/CT in the Staging of Lung Cancer
Farsad, Mohsen
[J]. CURRENT RADIOPHARMACEUTICALS, 2020, 13 (03) : 195 - 203

← 1 2 3 4 5 →